Clascoterone is a topical medication used to treat androgenetic alopecia, a common form of hair loss that affects both men and women. It works by blocking androgen receptors in the scalp, which reduces the production of sebum and hair miniaturization. Clascoterone is considered a novel androgen receptor inhibitor and has a similar safety profile to vehicle cream, but may cause mild skin reactions and HPA axis suppression.
Androgenetic alopecia is a genetic condition that affects millions of people worldwide. It is characterized by progressive hair loss, typically on the scalp, and can lead to baldness in severe cases. While there are many treatments available for hair loss, including hair transplant surgery and medications like minoxidil and finasteride, clascoterone is a promising new option that has shown positive results in clinical trials. If approved by the FDA for hair loss, it would be the first topical anti-androgen for hair loss in both men and women.
Overview of Clascoterone
Clascoterone, also known as cortexolone 17α-propionate or CB-03-01, is a novel androgen receptor inhibitor. It is currently being developed as a topical solution for androgenetic alopecia, a common form of hair loss that affects both men and women.
Mechanism of Action
Clascoterone works by blocking the action of dihydrotestosterone (DHT), a hormone that is known to contribute to hair loss. DHT is formed when testosterone interacts with the enzyme 5-alpha-reductase, and it binds to androgen receptors in hair follicles, causing them to shrink and eventually stop producing hair. Clascoterone competes with DHT for binding to androgen receptors, thereby reducing the harmful effects of DHT on hair follicles.
Comparison with Other Treatments
Clascoterone is a promising new treatment for androgenetic alopecia, and it has several advantages over existing treatments. For example, it is a topical solution that can be applied directly to the scalp, which minimizes the risk of systemic side effects. In addition, it has a novel mechanism of action that targets the underlying cause of androgenetic alopecia, rather than just treating the symptoms.
Other treatments for androgenetic alopecia include finasteride and minoxidil. Finasteride is an oral medication that inhibits the production of DHT, while minoxidil is a topical solution that promotes hair growth. However, both of these treatments have limitations. Finasteride can cause side effects such as decreased libido and erectile dysfunction, while minoxidil is not effective for everyone and can cause scalp irritation.
Clascoterone shows great promise as a safe and effective treatment for androgenetic alopecia. Further research is needed to fully understand its potential benefits and limitations, but it represents an exciting new development in the field of hair loss treatment.
Clinical Studies on Clascoterone and Hair Loss
Efficacy in Androgenetic Alopecia
Clascoterone is a novel topical androgen receptor-blocking drug that has shown promise in the treatment of androgenetic alopecia, also known as male pattern hair loss. According to a study published in the Journal of Clinical and Experimental Dermatology Research, clascoterone has been found to have comparable efficacy to established treatments such as minoxidil and finasteride for androgenetic alopecia. In vitro studies also demonstrated that clascoterone has the same efficacy as finasteride.
A multicenter phase 3 clinical trial for clascoterone, named Breezula®, is currently underway for male pattern hair loss. Patient recruitment began in June 2023, and both studies are expected to be completed by early 2025, according to HairScience.org.
Safety Profile and Side Effects
Clascoterone has been found to have a favorable safety profile in preliminary industry studies. Phase II trials in acne have not demonstrated evidence of systemic effects such as adrenal suppression, according to a study published in the Clinical and Experimental Dermatology journal.
In a study to evaluate the efficacy and safety of clascoterone solution for male pattern hair loss, the treatment was found to be effective and safe, and the drug was well-tolerated by subjects. The study compared the Clascoterone solution to a placebo, and the results showed that the Clascoterone solution was effective in helping people with male pattern hair loss to recover.
Clascoterone has shown promise as a novel treatment for androgenetic alopecia, with comparable efficacy to established treatments and a favorable safety profile. Further studies are needed to fully understand the long-term effects and potential side effects of this treatment.
Application and Usage
According to the Mayo Clinic, Clascoterone cream is typically applied to the affected area(s) of the scalp twice daily, with an interval of approximately 12 hours between applications. The recommended dosage may vary depending on the severity of the condition and the patient’s response to treatment. It is important to follow the instructions provided by a healthcare professional or the medication label.
Before applying Clascoterone cream, the patient should wash their hands with soap and water. The affected area(s) of the scalp should be gently washed and dried before applying a thin, even layer of the cream. The cream should not be applied to windburned or sunburned skin or on open wounds.
It is important to note that Clascoterone cream is for external use only and should not be ingested. In case of accidental ingestion, the patient should seek medical attention immediately.
Clascoterone cream is a promising treatment option for androgenetic alopecia, but it is important to follow the recommended dosage and application techniques to ensure safe and effective treatment.
FDA Approval Process
Clascoterone is a novel androgen receptor inhibitor that has recently been approved by the US FDA for the treatment of acne vulgaris in patients aged 12 years and older. The drug is marketed under the brand name Winlevi® and is available as a topical cream and solution. The approval of Winlevi® was based on the results of two pivotal Phase III clinical trials, which demonstrated the efficacy and safety of clascoterone in reducing acne lesions.
The FDA approval process for clascoterone was initiated in 2019, and the drug was granted priority review status due to its potential to address an unmet medical need. The priority review designation is reserved for drugs that offer significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions. The FDA’s decision to grant priority review status to clascoterone underscores the urgent need for new treatments for acne vulgaris.
Clascoterone is currently under review by regulatory agencies in several other countries, including the European Medicines Agency (EMA) and Health Canada. The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of clascoterone for the treatment of acne vulgaris, and the drug is currently under review by the European Commission for final approval. Health Canada has also completed its review of clascoterone and has granted market authorization for the drug under the brand name Winlevi®.
In addition to the US, Europe, and Canada, clascoterone is also being evaluated for regulatory approval in other regions, including Asia and Latin America. The regulatory approval process for clascoterone varies by country and region, but typically involves a review of the safety and efficacy data from clinical trials, as well as an assessment of the drug’s manufacturing and quality control processes. Once approved, clascoterone will be available to patients in these regions as a new treatment option for acne vulgaris.
Market Availability and Access
Clascoterone is a prescription medication and cannot be purchased over-the-counter. It is only available with a prescription from a licensed healthcare provider. Patients who are interested in using clascoterone to treat hair loss should consult with their healthcare provider to determine if it is a suitable treatment option for them.
Cost and Insurance Coverage
The cost of clascoterone can vary depending on a number of factors, including the patient’s location, the pharmacy where it is purchased, and the patient’s insurance coverage. Patients who have insurance coverage may be able to obtain clascoterone at a lower cost than those who do not.
It is important for patients to check with their insurance provider to determine if clascoterone is covered under their plan. Some insurance plans may require prior authorization before covering the cost of the medication. Patients without insurance coverage may be able to obtain clascoterone at a discounted price through patient assistance programs or other financial assistance programs offered by the manufacturer.
In summary, clascoterone is a prescription medication that is only available with a prescription from a licensed healthcare provider. The cost of the medication can vary depending on a number of factors, and patients should check with their insurance provider to determine if clascoterone is covered under their plan.
Future Research and Developments
Clascoterone is a promising treatment for androgenetic alopecia, and there is ongoing research to further understand its potential benefits and limitations.
One area of research is investigating the optimal dosage and duration of treatment. Currently, the recommended dosage for clascoterone is 7.5% cream applied twice daily. However, studies are being conducted to determine if lower doses and/or less frequent application can still provide beneficial results while reducing the risk of side effects.
Another area of research is exploring the potential of combining clascoterone with other hair loss treatments. For example, a study published in the Journal of the American Academy of Dermatology found that a combination of clascoterone and minoxidil was more effective in promoting hair growth than either treatment alone. Further research is needed to determine the safety and efficacy of combining clascoterone with other hair loss treatments.
In addition, researchers are investigating the use of clascoterone for other dermatological conditions, such as hirsutism and acne. A study published in the Journal of the European Academy of Dermatology and Venereology found that clascoterone was effective in reducing facial hair growth in women with hirsutism. Further research is needed to determine the optimal dosage and duration of treatment for hirsutism and other dermatological conditions.
While clascoterone shows promise as a treatment for androgenetic alopecia, further research is needed to fully understand its potential benefits and limitations. As research continues, it is possible that new developments in clascoterone treatment will emerge, providing even more effective options for those experiencing hair loss.
Frequently Asked Questions
Breezula (clascoterone) has completed Phase 3 clinical trials for androgenetic alopecia (AGA), also known as male or female pattern baldness. The trials showed that Breezula was effective in reducing hair loss and increasing hair growth compared to a placebo. In one study, Breezula demonstrated a statistically significant improvement in hair growth after 24 weeks of treatment.
As of December 2023, Breezula is not yet approved by the FDA for hair loss treatment. However, it has been approved for the treatment of acne vulgaris in adults and adolescents.
Breezula and finasteride are both medications used to treat hair loss, but they work in different ways. Finasteride is a prescription oral medication that blocks the conversion of testosterone to dihydrotestosterone (DHT), a hormone that causes hair loss. Breezula, on the other hand, is a topical medication that inhibits the androgen receptor, which is responsible for the effects of DHT on hair follicles. While both medications have shown efficacy in treating hair loss, Breezula may have fewer side effects than finasteride.
As of December 2023, there is no official release date for Breezula as a hair loss treatment. The approval process for new medications can take several years, and it is currently undergoing regulatory review by the FDA.
Winlevi (clascoterone) is a topical medication approved for the treatment of acne vulgaris in adults and adolescents. While it has not been specifically studied for hair loss, its mechanism of action suggests that it may have potential as a hair loss treatment. However, more research is needed to determine its efficacy for this indication.
Clascoterone works by inhibiting the activity of dihydrotestosterone (DHT), a hormone that causes hair loss in people with androgenetic alopecia (AGA). DHT binds to androgen receptors in hair follicles, causing them to shrink and eventually stop producing hair. Clascoterone blocks the androgen receptor, preventing DHT from binding and causing hair loss.
Discover real, drug-free solutions in our e-book, backed by clinical research.
-Anti-inflammatory strategies for improved blood flow to the scalp
-How to balance estrogen and prolactin naturally
-The downside of frequently wearing hats
-Organic alternatives to Rogaine
-Ditching sulfates for a healthier scalp
-Unbound iron and its role in oxidative stress
And much more!
This website participates in the Amazon Associates Program. Posts may contain links that result in an affiliate commission for the site owners if a qualifying purchase is made.